Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "China"

382 News Found

Lonza completes expansion of API manufacturing Lab in Nansha, China
News | March 08, 2022

Lonza completes expansion of API manufacturing Lab in Nansha, China

The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers


Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.
Biotech | March 06, 2022

Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.

Around 85% of ALS patients suffer from a progressive loss of bulbar functionality


China’s NMPA accepts supplemental NDA for Carteyva
Drug Approval | February 28, 2022

China’s NMPA accepts supplemental NDA for Carteyva

The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China


World’s first clinical trial for 3D bioprinted stem cell vascular grafts in China
Biotech | February 22, 2022

World’s first clinical trial for 3D bioprinted stem cell vascular grafts in China

Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.


Sputnik Light gets a boost as China changes rules on boosters
News | February 21, 2022

Sputnik Light gets a boost as China changes rules on boosters

Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters


CanSinoBIO's Convidecia approved as heterologous booster in China
News | February 21, 2022

CanSinoBIO's Convidecia approved as heterologous booster in China

Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants


Lupin ties up with Foncoo of China
News | January 19, 2022

Lupin ties up with Foncoo of China

This is the company’s first partnership arrangement in China


China approves MIOK Keratoprosthesis’ artificial cornea
Biotech | January 19, 2022

China approves MIOK Keratoprosthesis’ artificial cornea

The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness


China approves Brii Bio’s antibody combination to neutralise Covid-19
Drug Approval | December 10, 2021

China approves Brii Bio’s antibody combination to neutralise Covid-19

Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA


CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China
Biotech | November 22, 2021

CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China

CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region